Last updated on April 16, 2014 at 12:50 EDT

NanoPass Technologies Grants a License to its Intradermal Delivery Device to Circassia for Use in Multiple Allergy Vaccine Fields

September 15, 2011

NES ZIONA, Israel, September 15, 2011 /PRNewswire/ –

NanoPass Technologies Ltd. (“NanoPass”), a pioneer in intradermal
(into-the-skin) delivery solutions for vaccines, announced today that it has
recently entered into a license agreement for the MicronJet(TM), its
microneedle intradermal delivery device, with Circassia Ltd. (Oxford, UK)
(“Circassia”), a specialty biopharmaceutical company focused on allergy and
autoimmune diseases.

The agreement will provide Circassia with a license to use the device
with many of Circassia’s products including its cat and ragweed allergy
therapies, which will enter phase III clinical trials in 2012. Financial
terms were not disclosed.

Yotam Levin, MD, Chief Executive Officer of NanoPass, commented, “We are
excited to enter into this license agreement with Circassia, a leading
allergy vaccine developer. We see a significant fit between the device we’ve
developed and Circassia’s patients’ needs. Along with the regulatory
approvals we have recently obtained from the FDA, Europe and other
regulatory bodies, securing a promising late-stage client is a key component
towards full commercialization of our product.

“We plan to make MicronJet a valuable component of our product
offerings, as it provides consistent and easy to use delivery to our target
location, the skin. We intend to use the device for many of our allergy
programs and have received extremely positive feedback from patients and
clinicians,” said Charles Swingland, Circassia’s Vice-Chairman.

About NanoPass Technologies

NanoPass Technologies was founded by Dr. Shuki Yeshurun and is backed by
prominent Israeli and US investors, including Ofer Hi Tech, D Partners, WFD
Ventures, and Elcam Medical.

About NanoPass’s MicronJet Device and Intradermal Immunization

MicronJet is a microneedle-based device for intradermal delivery of
vaccines and drugs. The device allows for consistent, reliable, and simple
delivery of the drugs directly into the skin. Injecting vaccines into the
skin harnesses the skin’s potent immunity, thereby significantly reducing
the amount of vaccine required for vaccination. Furthermore, the device may
induce superior immunogenicity while maintaining a lower dose than
conventional doses delivered into the muscle.

About Circassia

Circassia is run by a team of highly experienced biotechnology
scientists and entrepreneurs, and is chaired by the former Chairman of
GlaxoSmithKline, Sir Richard Sykes. The company is based in the UK on the
Oxford Science Park, and in Hamilton, Canada, where its joint venture Adiga
Life Sciences is located. Its ToleroMune technology was developed originally
by scientists at Imperial College, London. Having successfully completed
four fundraising rounds Circassia is backed by a syndicate of world-class
venture capital and institutional investors, including Imperial Innovations
and Invesco Perpetual.

Circasssia is developing a range of allergy T-cell vaccines based on its
proprietary ToleroMune(R) technology. The company has successfully completed
a number of phase II studies with its cat, house dust mite and ragweed
allergy products, and its grass allergy therapeutic is in clinical testing.
Clinical results to date show that short treatment regimes with Circassia’s
T-cell vaccines can greatly reduce patients’ allergic reactions, without the
need for adjuvants or other immune stimulators, while proving extremely well
tolerated. As a result, the treatments offer major potential clinical
benefits compared with existing therapies, and have significant market
opportunities. Over 150 million people suffer from allergic rhinitis in the
US and Europe, and the current treatment market is approximately $12 billion
per year.

        Yotam Levin, CEO:
        +972-8-9462905 +972-523-392727

SOURCE NanoPass Technologies LTD.

Source: PR Newswire